TRNS vs. TXG, SENS, CTKB, LAB, ALNT, EYPT, AEHR, QTRX, QSI, and NAUT
Should you be buying Transcat stock or one of its competitors? The main competitors of Transcat include 10x Genomics (TXG), Senseonics (SENS), Cytek Biosciences (CTKB), Standard BioTools (LAB), Allient (ALNT), EyePoint Pharmaceuticals (EYPT), Aehr Test Systems (AEHR), Quanterix (QTRX), Quantum-Si (QSI), and Nautilus Biotechnology (NAUT). These companies are all part of the "measuring and control equipment" industry.
Transcat vs.
10x Genomics (NASDAQ:TXG) and Transcat (NASDAQ:TRNS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.
Transcat has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.
In the previous week, 10x Genomics had 31 more articles in the media than Transcat. MarketBeat recorded 32 mentions for 10x Genomics and 1 mentions for Transcat. Transcat's average media sentiment score of 1.81 beat 10x Genomics' score of 0.15 indicating that Transcat is being referred to more favorably in the news media.
Transcat received 151 more outperform votes than 10x Genomics when rated by MarketBeat users. Likewise, 66.14% of users gave Transcat an outperform vote while only 51.72% of users gave 10x Genomics an outperform vote.
10x Genomics has a beta of 1.85, meaning that its share price is 85% more volatile than the S&P 500. Comparatively, Transcat has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.
10x Genomics currently has a consensus price target of $20.57, suggesting a potential upside of 88.73%. Transcat has a consensus price target of $111.50, suggesting a potential upside of 39.64%. Given 10x Genomics' higher probable upside, equities analysts plainly believe 10x Genomics is more favorable than Transcat.
84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 98.3% of Transcat shares are owned by institutional investors. 10.0% of 10x Genomics shares are owned by company insiders. Comparatively, 2.3% of Transcat shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Transcat has a net margin of 6.22% compared to 10x Genomics' net margin of -29.90%. Transcat's return on equity of 7.23% beat 10x Genomics' return on equity.
Summary
Transcat beats 10x Genomics on 12 of the 18 factors compared between the two stocks.
Get Transcat News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRNS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Transcat Competitors List
Related Companies and Tools
This page (NASDAQ:TRNS) was last updated on 2/21/2025 by MarketBeat.com Staff
